ReviewPharmaceuticals (Basel, Switzerland)2026
Role of the Blood-Brain Barrier in the Pathophysiology of Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A Comparative Review.
Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The blood-brain barrier (BBB) is a unique neurovascular interface essential for central nervous system homeostasis. Beyond its classical protective role, accumulating evidence points to the BBB as a dynamic structure actively involved in brain function in health and disease. The present review synthesizes clinical, molecular, and neuroimaging evidence implicating BBB dysfunction in major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia. The paper was prepared in accordance with the recommendations of the Scale for the Assessment of Narrative Review Articles and was based on a PubMed search of publications published between 2000 and 2026. We summarize BBB architecture and regulation within the neurovascular unit and examine how neuroinflammation, oxidative stress, mitochondrial dysfunction, vascular-metabolic disturbances, and glucocorticoid signaling compromise tight junction, endothelial, pericyte, and astrocytic function, thereby facilitating peripheral immune signaling and sustaining central inflammation. Disorder-specific findings highlight shared and distinct mechanisms: In MDD, EZH2-mediated downregulation of claudin-5 and VEGF-driven barrier disruption are associated with increased permeability in the prefrontal cortex and hippocampus; in BD, elevated cerebrospinal fluid/serum albumin ratios and levels of S100B and matrix metalloproteinase-9-mediated tight junction degradation are associated with illness duration and neuroprogression; and in schizophrenia, reduced expression of claudin-5 and claudin-11, diminished pericyte coverage, and dysregulation of transforming growth factor-α/platelet-derived growth factor signaling are associated with neuroinflammation and treatment resistance. Therapeutic implications are discussed, including anti-inflammatory and antioxidant strategies, endothelial stabilization, and BBB-targeted delivery, as well as methodological limitations and future directions for biomarker development and neurovascular modeling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.